Commentary on Ezard et al.: Agonist-based medications for stimulant use disorder-Distinguishing their true colours.
作者信息
Tardelli Vitor S, Fidalgo Thiago M
机构信息
Mental Health and Addictions Services, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.
出版信息
Addiction. 2025 Jul;120(7):1363-1365. doi: 10.1111/add.70091. Epub 2025 May 8.
Abstract
摘要
相似文献
1
Commentary on Ezard et al.: Agonist-based medications for stimulant use disorder-Distinguishing their true colours.对埃扎德等人的评论：用于兴奋剂使用障碍的基于激动剂的药物——辨别它们的真面目。
Addiction. 2025 Jul;120(7):1363-1365. doi: 10.1111/add.70091. Epub 2025 May 8.
2
Commentary on Ezard et al.: Prescribed psychostimulant medications for methamphetamine use disorder - an urgent path forward.对埃扎德等人的评论：用于甲基苯丙胺使用障碍的处方精神刺激药物——一条紧迫的前进道路。
Addiction. 2025 Jul;120(7):1360-1362. doi: 10.1111/add.70058. Epub 2025 Apr 1.
3
Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants.注意缺陷多动障碍（ADHD）青少年和成人的药物干预：兴奋剂和非兴奋剂药物以及处方兴奋剂的滥用。
Psychol Res Behav Manag. 2014 Sep 9;7:223-49. doi: 10.2147/PRBM.S47013. eCollection 2014.
4
Commentary on Young et al.: Clinical guidance is required for stimulant co-prescription with opioid agonist therapy.对杨等人的评论：兴奋剂与阿片类激动剂疗法联合处方需要临床指导。
Addiction. 2025 Jun;120(6):1195-1197. doi: 10.1111/add.70061. Epub 2025 Apr 4.
5
Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.治疗兴奋剂使用障碍的处方精神兴奋剂：系统评价和荟萃分析。
Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255. doi: 10.1007/s00213-020-05563-3. Epub 2020 Jun 29.
6
Lisdexamfetamine-Induced Psychosis in a Patient With a Neurodevelopmental Disorder.一名患有神经发育障碍的患者出现赖右苯丙胺所致精神病
Cureus. 2024 Jan 31;16(1):e53349. doi: 10.7759/cureus.53349. eCollection 2024 Jan.
7
The Use of Lisdexamfetamine to Treat ADHD in a Patient with Stimulant (Methamphetamine) Use Disorder.使用赖右苯丙胺治疗患有兴奋剂（甲基苯丙胺）使用障碍的多动症患者。
Case Rep Psychiatry. 2023 Aug 14;2023:5574677. doi: 10.1155/2023/5574677. eCollection 2023.
8
[Stimulant and non-stimulant medication in current and future therapy for ADHD].[兴奋剂和非兴奋剂药物在当前及未来多动症治疗中的应用]
Fortschr Neurol Psychiatr. 2012 Mar;80(3):130-40. doi: 10.1055/s-0031-1273223. Epub 2011 May 24.
9
Treatment of stimulant use disorder: A systematic review of reviews.兴奋剂使用障碍的治疗：系统评价综述。
PLoS One. 2020 Jun 18;15(6):e0234809. doi: 10.1371/journal.pone.0234809. eCollection 2020.
10
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.注意缺陷多动障碍：儿科药物治疗的最新进展。
Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.
本文引用的文献
1
Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial.赖右苯丙胺治疗甲基苯丙胺成瘾：一项随机、安慰剂对照试验。
Addiction. 2025 Jul;120(7):1345-1359. doi: 10.1111/add.16730. Epub 2024 Dec 19.
2
Reductions in Substance Use as Outcome Targets for Treatment Development.减少物质使用作为治疗开发的结果目标。
Am J Psychiatry. 2024 Nov 1;181(11):947-948. doi: 10.1176/appi.ajp.20240841.
3
Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.治疗苯丙胺类兴奋剂使用障碍的处方精神兴奋剂：随机安慰剂对照试验的系统评价和荟萃分析。
Addiction. 2024 Feb;119(2):211-224. doi: 10.1111/add.16347. Epub 2023 Oct 25.
4
A Systematic Review of the Efficacy of Contingency Management for Substance Use Disorders in Low and Middle Income Countries.一项针对中低收入国家物质使用障碍的效价管理疗效的系统评价。
Int J Behav Med. 2024 Aug;31(4):605-619. doi: 10.1007/s12529-023-10197-8. Epub 2023 Aug 2.
5
Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk.阿片类药物使用障碍和共患精神兴奋剂使用障碍患者中处方苯丙胺开始使用丁丙诺啡：治疗保留和过量风险分析。
BMJ Ment Health. 2023 Jul;26(1). doi: 10.1136/bmjment-2023-300728.
6
Contingency Management for Stimulant Use Disorder: Progress, Challenges, and Recommendations.《物质使用障碍的权变管理：进展、挑战和建议》。
J Ambul Care Manage. 2023;46(2):152-159. doi: 10.1097/JAC.0000000000000450. Epub 2023 Feb 3.
7
Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial.拉右旋苯丙胺治疗急性甲基苯丙胺戒断：一项可行性和安全性的初步试验。
Drug Alcohol Depend. 2022 Dec 1;241:109692. doi: 10.1016/j.drugalcdep.2022.109692. Epub 2022 Nov 7.
8
Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder.阿片类药物使用障碍患者接受丁丙诺啡治疗时的兴奋剂处方和与药物相关的中毒风险分析。
JAMA Netw Open. 2022 May 2;5(5):e2211634. doi: 10.1001/jamanetworkopen.2022.11634.
9
Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial.美沙酮辅助治疗阿片类药物使用障碍的临床效果：一项随机对照试验
J Psychopharmacol. 2021 Nov;35(11):1420-1430. doi: 10.1177/02698811211050563. Epub 2021 Oct 26.
10
Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study.口服右苯丙胺治疗成年轻度至中度甲基苯丙胺依赖的安全性和耐受性：一项 2 期剂量递增研究。
BMJ Open. 2021 May 18;11(5):e044696. doi: 10.1136/bmjopen-2020-044696.
Zotero 插件